Abstract: A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.

Abstract: The present invention relates to a process for preparing a mixture M1 of enol phosphate isomers devoid of (E,E) isomer and comprising at least 98% of (E,Z) isomer, at least 0.1% of (Z,Z) isomer and at least 0.1% of (Z,E) isomer, comprising bringing a mixture of isomers of said enol phosphate comprising a detectable amount of (E,E) isomer into contact with a hydrolysable dienophile in an organic solvent, followed by base hydrolysis of the medium obtained and elimination of the adduct formed, in order to obtain the mixture M1 devoid of (E,E) isomer.

Abstract: A focus adjustment method for acquiring an image of a surface of interest of a sample by a holographic imager includes the steps of: placing the sample including at least one reference object having a known shape and described by characterising parameters having at least position parameters acquiring an image and determining the position of the reference object with respect to the acquisition plane, by applying a light diffraction model involving the spatial parameters of the reference object estimated by approximating the appearance of the reference object in the holographic image acquired, and determining the position of the surface of interest with respect to the acquisition plane from a position of the reference object and focus adjustment of the image acquisition.

Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.

Abstract: The invention relates to a method of processing data representative of a person’s binocular motricity, the method comprising the following steps: stimulating the binocular motricity of a person by means of a binocular motricity stimulation device (21) configured to specifically stimulate saccades, vergences or a combination of both or of a reading test (22); physical stimuli in 3D real space seen with both eyes naturally (without artifices); acquiring the movement of the right eye (RE) and the left eye (LE) of a person (P) during said stimulation and, if applicable, a stimulation signal from the binocular motor stimulation device; the method comprising the following steps implemented in a processing unit (3); determination from the movement of the left eye (LE) and the right eye (RE), of an effective trajectory (Tr1) of the eyes in response to each stimulation, an effective trajectory corresponding to a saccade and/or a vergence movement of the eyes.

Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Abstract: The invention relates to a method for increasing the lifespan of animal sperm comprising contacting said sperm with an inhibitor of Slo3 potassium channel. The invention also relates to a use of an inhibitor of Slo3 potassium channel, for increasing the lifespan of animal sperm or motility of capacitated animal sperm, comprising contacting an inhibitor of Slo3 potassium channel with said sperm. Moreover, the invention relates to an artificial insemination instrument for use in artificial insemination of an animal, comprising animal sperm in contact with an inhibitor of Slo3 potassium channel. The invention also relates to a method for artificially inseminating an animal using said artificial insemination instrument. Eventually, the invention relates to a method for increasing the fertility of an animal, comprising contacting sperm of said animal with an inhibitor of Slo3 potassium channel; then artificially inseminating said animal with said sperm.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: The present invention relates to phage T5 capsids that are devoid of genomic DNA from the phage and exposing, on their surface, at least one fusion protein of interest.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: A method for chemically functionalizing a cellulosic material using a diazo compound, and the functionalized cellulosic materials obtained by the method. The cellulosic materials may be functionalized with a functional groups selected from hydrophobic agents, catalyzing agents, sensing agent, diagnostic agents, printing agents chelating agents, ligands, antioxidants, antimicrobial agents, or drugs. Also, the uses of functionalized cellulosic materials obtained by the method in a variety of applications.

Abstract: The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA.

Abstract: The present invention relates to an electrode comprising an electrically conductive substrate of which at least one portion of the surface is covered with a metal deposit of copper, the surface of said deposit being in an oxidised, sulphurised, selenised and/or tellurised form and the deposit having a specific surface area of more than 1 m2/g; a method for preparing such an electrode; and a method for oxygenising water with dioxygen involving such an electrode.

Abstract: Chemoenzymatic process for coproducing a disulfide and a sulfoxide or a sulfone The present invention relates to a chemoenzymatic process for coproducing disulfide and sulfoxide or sulfone from a composition M comprising: 1) a sulfide, 2) optionally an oxidizing agent, 3) an organic compound bearing at least one thiol group, 4) an enzyme E catalyzing the oxidation of said sulfide to sulfoxide or to sulfone, 5) an enzyme D catalyzing the formation of a disulfide bridge between two equivalents of said organic compound bearing at least one thiol group to form a dimer, and 6) a cofactor common to the two enzymes E and D; and also to a composition enabling especially the implementation of this process. The present invention also relates to the use of a mercaptan for reducing a disulfide bridge formed between two equivalents of an organic compound bearing at least one thiol group, and more particularly to the use thereof as regeneration substrate of the process described above.

Abstract: Optical device for optical fluorescence microscopy, comprising a spatial modulator (1), a microscope objective (2), a beamsplitter (3) and a camera (4), wherein the beamsplitter (3) is placed between the spatial modulator (1) and the microscope objective (2), wherein the beamsplitter (3) is placed between the camera (4) and the microscope objective (2), and wherein a prism (5) is placed between the beamsplitter (3) and the camera (4).

Abstract: The present disclosure relates to a novel staged-synthesis method for introduction of various metals in the structure of zeolite frameworks by isomorphous substitution. This new method is based on a hydrothermal synthesis in which the metal addition to the precursor suspensions (gel) is delayed. This so-called “staged-synthesis method” allows to obtain nanosized silanol highly homo-geneous crystalline zeolite structures with a control of the metal location.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: A calibration standard for determining an intensity decay related to an evanescent field generated close to the interface between a sample to be tested and a substrate on which the sample is to be deposited, preparation and analysis methods and use thereof.